The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients

Materia Medica

Status and phase

Enrolling

Phase 3

Conditions

Rhinosinusitis Acute

Rhinosinusitis

Treatments

Drug: Raphamin

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT06901297

MMH-407-011

Details and patient eligibility

About

Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial of the efficacy and safety of Raphamin in the treatment of acute rhinosinusitis in adult patients.

Full description

A multicenter, double-blind, placebo-controlled, randomized, parallel-group clinical trial.

The trial will enroll outpatients of either gender aged 18 to 75 years with clinical manifestations of acute rhinosinusitis (ARS) within the first 48 hours after the disease onset. Patient recruitment will be conducted during the seasonal incidence of acute respiratory viral infection (ARVI). After the patient signs the information sheet and informed consent form for participation in the clinical trial, the medical history will be collected, thermometry, objective examination, laboratory tests will be performed, concomitant diseases and concomitant therapy will be recorded. The severity of ARS symptoms will be assessed using Major Symptom Score (MSS). Initially (Day 1) and on Visits 2 (Day 4) and 3 (Day 7), the patient together with the investigator, fills in the MSS scale and completes the Sino-Nasal Outcome Test questionnaire for assessing the quality of life of patients with diseases of the nose and paranasal sinuses (SNOT-22).

If all inclusion criteria are met and there no any exclusion criteria, at Visit 1 (Day 1), the patient is randomized into one of two groups: Group 1 patients will receive Raphamin according to the dosage regimen for 5 days; Group 2 patients will receive Placebo using the Raphamin dosage regimen for 5 days.

The trial uses an electronic patient diary (EPD) where the patient daily morning and evening will make records axillary body temperature (measured with a classic mercury-free thermometer) and symptoms of the disease (according to the MSS). In addition, administration of basic therapy drugs (if applicable) as well as any possible worsening of the patient's condition (if applicable, to assess safety / to record adverse events) should also be recorded in the patient diary. The investigator will instruct the patient on how to complete the diary. At Visit 1, the patient will record the severity of ARS symptoms and body temperature in the diary together with the physician.

The patient will be observed for 14 days (screening, randomization - up to 1 day, treatment - 5 days, follow-up - up to 14 days).

During the treatment and follow-up period, patients/physicians will pay 3 visits, on days 1, 4 and 7 (Visits 1, 2 and 3) - at a medical center or at home; a phone visit (Visit 4) will be on day 14.

At Visits 2 and 3, the investigator performs objective examination, records changes in the disease symptoms, concomitant therapy, and controls the filling of the diary, evaluates the patient's compliance (Visit 3). At Visit 4 (a phone visit), the investigator evaluates safety, collects information about the patient's condition, the presence/absence of complications, the use of antibiotics, and the presence/absence of hospitalization of the patient.

Symptomatic therapy and therapy for concomitant diseases will be permitted during the trial except for the drugs listed under "Prohibited Concomitant Treatment".

Enrollment

552 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male and female aged 18 - 75 years.
Diagnosis of acute rhinosinusitis:
- 8-12 points on MSS scale;
- no more than 3 severe symptoms (3 points on the MSS scale)
- facial pain/heaviness in the facial area 1-2 points on the MSS scale.
Disease duration up to 48 hours (from the onset of the first symptoms of the disease).
Availability of a patient information sheet and an informed consent form for participation in the clinical trial signed by the patient.
Patients who agreed to use a reliable method of contraception during the study (for men and women of reproductive potential).

Exclusion criteria

Symptoms of acute bacterial rhinosinusitis (three or more of those below):
- fever of ≥ 38.0°C;
- the second wave of ARS symptoms;
- one-sided process;
- facial pain/pressure of 3 points (on the MSS scale).
Recurrent ARS (≥4 episodes of ARS per year with complete resolution of symptoms between episodes).
Odontogenic rhinosinusitis.
Allergic (seasonal or year-round) rhinitis.
Nasal polyps or clinically significant nasal septum deviation.
Concomitant otitis.
Use of intranasal or systemic corticosteroids for 30 days prior to the screening visit.
Use of intranasal or systemic antibiotics for 30 days prior to the screening visit.
Surgery for the nasal cavity and paranasal sinuses during the last 6 months before the screening visit.
Any other surgery during the last 3 months.
Clinical symptoms of severe influenza/ARVI requiring hospitalization.
Suspected bacterial infection of any localization requiring the administration of antibiotics from the first day of disease.
History/suspicion of oncology of any localization (except for benign neoplasms).
Exacerbation or decompensation of chronic diseases (diabetes mellitus, bronchial asthma, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia, malformations of the respiratory and ENT organs, etc.) affecting the patient's ability to participate in the clinical trial.
Previously diagnosed immunodeficiency of any etiology.
Unstable angina or myocardial infarction during the last 6 months.
Class III and IV chronic heart failure (according to the classification of the New York Heart Association, 1964).
History of chronic kidney disease (classes C3-5 A3).
History of liver failure (class C according to Child-Pugh).
Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia.
Pregnancy, breast-feeding, and childbirth less than 3 months before inclusion in the trial.
Hypersensitivity to any component of the medicines used in the treatment.
Patients who used medications listed under "Prohibited Concomitant Treatment" within 1 month prior to inclusion in the trial or need medications prohibited for use in the trial.
Patients who, from the investigator's point of view, will not comply with the observation requirements during the trial or follow the procedure for taking the test drugs.
History of mental illness, alcoholism, drug abuse, which, from the investigator's point of view, will prevent the patient from following the trial procedures.
Participation in other clinical trials within 3 months prior to inclusion in this trial.
Patient is related to on-site research personnel directly involved in the trial, or is the immediate family member of the investigator. 'Immediate family members' mean spouses, parents, children, or siblings, whether related or adopted.
Patient is employed by OOO "NPF "MATERIA MEDICA HOLDING", i.e., is an employee of the company, a temporary contract employee, or a designated official responsible for conducting the trial or their immediate family member.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

552 participants in 2 patient groups, including a placebo group

Raphamin

Experimental group

Description:

Per os without food. The tablet should be kept in mouth until completely dissolved. On day 1 of treatment, 8 tablets should be taken using the following regimen: 1 tablet every 30 minutes for the first 2 hours (5 tablets in total for 2 hours), then 1 more tablet 3 times at equal intervals during the same day. On day 2 and onwards, 1 tablet should be taken 3 times a day. The duration of treatment is 5 days.

Treatment:

Drug: Raphamin

Placebo

Placebo Comparator group

Description:

Placebo using the Raphamin dosage regimen.

Treatment:

Drug: Placebo